共查询到20条相似文献,搜索用时 93 毫秒
1.
2.
自微乳化释药系统研究进展 总被引:2,自引:0,他引:2
近年来,药剂学领域出现许多增加水难溶性药物溶解度和吸收的技术,其中自乳化释药系统(self-emulsifying drugdelivery systems,SEDDS)得到了广泛的发展。SEDDS 是由药物、油、乳化剂及助溶剂等组成的一种油状混合物,在体外轻微振荡或体内胃肠道的蠕动下自发的形成一种热力学稳定的乳状液,其粒径大约100~300 nm,粒径小于100 nm的乳剂称为自微乳化释药系统(self-microemulsifying drugdelivery systems,SMEDDS)。与 SEDDS 相比,SMEDDS 的最大优点是粒径小、溶液澄清透明、药物增溶量大、制剂更稳定。本文就 SMEDDS 的处方组成、结构与理化性质、质量评价以及应用等方面作一简要综述。1 处方组成SEDDS 的基本处方组成包括药物、油、乳化剂及助溶剂等。SMEDDS 的基本处方组成与 SEDDS 相同,其特殊性在 相似文献
3.
4.
自乳化释药系统的研究进展 总被引:11,自引:0,他引:11
从自乳化释药系统的基本概念、研究方法、影响因素等方面出发,对其在药学方面应用的特点及质量要求等进行讨论,并对自乳化释药系统的发展前景作了综述。 相似文献
5.
本文对近几年国内外有关自乳化药物传递系统的特点、吸收机制、组成、影响因素及其在药剂学方面的应用进行了归纳和分析。自乳化药物传递系统可显著地提高难溶性或亲脂性药物口服生物利用度,具有广阔的发展前景。 相似文献
6.
7.
自乳化给药系统因可提高药物的吸收速度和程度,增强难溶性药物的溶解能力,提高生物利用度而成为当前药剂研究的一大热点。本综述就近几年国内外关于自乳化给药系统的最新研究进展作一简要介绍。 相似文献
8.
9.
自乳化释药系统的探讨 总被引:1,自引:0,他引:1
自乳化药物传递系统可改善药物的口服吸收,增加其生物利用度,是克服某些脂溶性或水难溶性药物制剂吸收困难的一种极具潜力的方法,本文从自乳化释药系统的基本概念、处方设计、质量评价等方面出发,对其在药学方面应用的特殊及质量要求等进行讨论。 相似文献
10.
本文将水不溶性药物葛根素制备成自乳化制剂。测定了葛根素在不同油相及表面活性剂的溶解度,结果表明葛根素在油酸、Tween 80中的溶解度较好,1,2-丙二醇不但能增加药物的溶解度,而且能够提高自乳化能力。以油酸为油相,Tween 80为表面活性剂,1,2-丙二醇为助表面活性剂,配制一系列混合物,通过绘制三元相图得到自乳化区,考察不同自乳化处方的自乳化性质,采用激光粒度散射仪测定乳化后粒子大小,在体外评价基础上选择较好的3个处方进行比格犬体内药动学研究,比较不同处方自乳化制剂在比格犬体内的生物利用度包括药代动力学参数Cmax, Tmax, AUC0-t。结果表明处方2和处方3的AUC0-t值[(5.201±0.511) ng·mL-1·h, (5.174±0.498) ng·mL-1·h]和Cmax值[(1.524±0.125) ng·mL-1, (1.513±0.157) ng·mL-1]显著高于处方4[(3.013±0.623) ng·mL-1·h, (0.939±0.089) ng·mL-1],通过体内研究结果获得较优处方为油酸(17.5%)、Tween 80(34.5%)、1,2-丙二醇(34.5%)。自乳化释药系统提供了水不溶性药物口服给药的新途径。 相似文献
11.
12.
13.
《Drug delivery》2013,20(3):258-265
AbstractTargeting drug system (TDS) or targeted drug delivery system (TDDS) is a new kind of drug delivery system which could make drug to be directly concentrated on the target site with high curative effects and low side-effects. As the quintessence of Chinese culture, traditional Chinese medicine (TCM) has a large advantage in many disease clinical treatments, especially in cancer, hypertension and many other intractable diseases owing to their low toxicity and side-effects relative to western medicine. This article reviews literatures on development of TCM-targeted preparations which were published in the past 10 years. TDS including active-targeting, passive-targeting and physical-chemical-targeting preparations were introduced through domestic and overseas literatures to reveal the unique advantages of TCM-targeting preparations in drug delivery system. In this article, we have reviewed some kinds of TCM-targeting preparations and indicated that great attention should be paid to the research on the TCM-targeting preparations. 相似文献
14.
15.
16.
The bioactive alkaloids (e.g. vincristine, hydroxycamptothecin, ligustrazine, and so on) from traditional Chinese medicine (TCM) have exerted potent efficacies (e.g. anti-tumor, anti-inflammation, immunosuppression, etc.). However, a series of undesirable physicochemical properties (like low solubility and weak stability) and baneful pharmacokinetic (PK) profiles (e.g. low bioavailability, short half time, rapid clearance, etc.) have severely restricted their applications in clinic. In addition, some side effects (like cumulative toxicities caused by high-frequency administration and their own toxicities) have recently been reported and also confined their clinical uses. Therefore, developments in drug delivery of such alkaloids are of significance in improving their drug-like properties and, thus, treatment efficiencies in clinic. Strategies, including (i) specific delivery via liposomes; (ii) sustained delivery via nanoparticles, gels, and emulsions; and (iii) transdermal delivery via ethosomes, solid lipid nanoparticles, and penetrating enhancers, have been reported to improve the pharmacokinetic and physicochemical characters of problematic TCM alkaloids, decline their adverse effects, and thus, boost their curative efficacies. In this review, the recent reports in this field were comprehensively summarized with the aim of providing an informative reference for relevant readers. 相似文献
17.
18.
19.
20.
中药和天然药物治疗肝纤维化的研究 总被引:8,自引:3,他引:8
肝纤维化是由于细胞外基质的合成大于降解导致过度沉积 ,是纤维增生与纤维分解不平衡而引起的病理过程。肝纤维化是大多数慢性肝病所共有的病理特征 ,也是慢性肝炎肝硬化等进一步发展、恶化的重要中间环节。因而 ,针对不同水平的调节因素以及纤维组织生成和降解机制 ,抗纤维化药物可以从不同环节抑制其生成或促进其降解。该文就治疗肝纤维化的中药和天然药物的研究现状作一简要综述。 相似文献